The European Lung Cancer Congress (ELCC 2022), from 30 March-2 April 2022, was held virtually this year and showcased recent developments in the prevention, screening, and early detection of thoracic malignancies, as well as the current and emerging contribution of precision medicine, big data and artificial intelligence, biomarkers and liquid biopsies in the optimal management of patients with lung cancer.
View all videos

ELCC 2022

European Lung Cancer Conference
30 Mar–02 April 2022 | Prague, Czech Republic
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

🎥 @GeorgetteOni of NHS Nottingham Breast Institute talks on supporting future generations of healthcare professionals

Watch: 👉http://ow.ly/LwxB50LQ3p0👈

@UKONSmember #UKONS2022 #Nursing #OncologyNursing

Reply on Twitter 1598709591365255173Retweet on Twitter 1598709591365255173Like on Twitter 1598709591365255173Twitter 1598709591365255173
Retweet on TwitterVJ Oncology Retweeted
myESMOESMO - Eur. Oncology@myESMO·
December 2, 2022

"As an oncology community, we must rise to the task today of laying the foundations for sustainable, high-quality #CancerCare that will remain accessible tomorrow", @peters_solange said at the Opening Ceremony for #ESMOAsia22.
👉http://ow.ly/XAbU50LTahQ

Reply on Twitter 1598557206957506561Retweet on Twitter 15985572069575065615Like on Twitter 159855720695750656131Twitter 1598557206957506561
Retweet on TwitterVJ Oncology Retweeted
pashtoonkasiPashtoon Kasi MD, MS@pashtoonkasi·
December 2, 2022

🧐TOPAZ-1➡️685 patients.
👇🏾Biomarker analysis👇🏾441 patients.
🛑244 (35.6%)‼️ testing NOT completed?

IDH1 8.8%
HER2 7.9%
FGFR2 3.4%
BRAF 3.6%
BRCA 4.3%
More realistic of real🌍numbers in 1st line.

💡upfront #ctDNA✅ 💯 ➡️you’ll find more. @OncoAlert @curecc #ESMOAsia22 @myESMO https://twitter.com/jdekervel/status/1598599792749600770

Jeroen Dekervel@JDekervel

Impact of molecular driver in #cholangiocarcinoma regarding #durvalumab benefit in #TOPAZ1. Exploratory but some signal for 🔽 efficacy in ERBB2 amp and IDH1mt and 🔼 efficacy in KRASmt. #ESMOAsia22 2

Reply on Twitter 1598644651665268736Retweet on Twitter 15986446516652687369Like on Twitter 159864465166526873634Twitter 1598644651665268736
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

#SABCS22 starts in only a couple of days!

Stay tuned right here 👉http://VJOncology.com👈 which will be updated soon on all the latest in #BreastCancer 👩‍⚕‍🎥🎙

@VJOncology @SABCSSanAntonio @AACR #BreastCancer #BCsm #OncoAlert

Reply on Twitter 1598694368269025282Retweet on Twitter 1598694368269025282Like on Twitter 15986943682690252822Twitter 1598694368269025282
Retweet on TwitterVJ Oncology Retweeted
matteolambeMatteo Lambertini, MD PhD@matteolambe·
December 2, 2022

Great comprehensive presentation by super @RebeccaDSing at #ESMOasia22 on #immunotherapy in early triple-negative #BreastCancer: important citation for the recent review by @ElisaAgostinett & the great algorithm for #TNBC treatment by @hoperugo

@OncoAlert @myESMO #bcsm #ImmOnc

4
Reply on Twitter 1598530488737619971Retweet on Twitter 15985304887376199716Like on Twitter 159853048873761997119Twitter 1598530488737619971
Load More

ELCC 2022

European Lung Cancer Conference
30 Mar–02 April 2022 | Prague, Czech Republic
The European Lung Cancer Congress (ELCC 2022), from 30 March-2 April 2022, was held virtually this year and showcased recent developments in the prevention, screening, and early detection of thoracic malignancies, as well as the current and emerging contribution of precision medicine, big data and artificial intelligence, biomarkers and liquid biopsies in the optimal management of patients with lung cancer.
View all videos
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

🎥 @GeorgetteOni of NHS Nottingham Breast Institute talks on supporting future generations of healthcare professionals

Watch: 👉http://ow.ly/LwxB50LQ3p0👈

@UKONSmember #UKONS2022 #Nursing #OncologyNursing

Reply on Twitter 1598709591365255173Retweet on Twitter 1598709591365255173Like on Twitter 1598709591365255173Twitter 1598709591365255173
Retweet on TwitterVJ Oncology Retweeted
myESMOESMO - Eur. Oncology@myESMO·
December 2, 2022

"As an oncology community, we must rise to the task today of laying the foundations for sustainable, high-quality #CancerCare that will remain accessible tomorrow", @peters_solange said at the Opening Ceremony for #ESMOAsia22.
👉http://ow.ly/XAbU50LTahQ

Reply on Twitter 1598557206957506561Retweet on Twitter 15985572069575065615Like on Twitter 159855720695750656131Twitter 1598557206957506561
Retweet on TwitterVJ Oncology Retweeted
pashtoonkasiPashtoon Kasi MD, MS@pashtoonkasi·
December 2, 2022

🧐TOPAZ-1➡️685 patients.
👇🏾Biomarker analysis👇🏾441 patients.
🛑244 (35.6%)‼️ testing NOT completed?

IDH1 8.8%
HER2 7.9%
FGFR2 3.4%
BRAF 3.6%
BRCA 4.3%
More realistic of real🌍numbers in 1st line.

💡upfront #ctDNA✅ 💯 ➡️you’ll find more. @OncoAlert @curecc #ESMOAsia22 @myESMO https://twitter.com/jdekervel/status/1598599792749600770

Jeroen Dekervel@JDekervel

Impact of molecular driver in #cholangiocarcinoma regarding #durvalumab benefit in #TOPAZ1. Exploratory but some signal for 🔽 efficacy in ERBB2 amp and IDH1mt and 🔼 efficacy in KRASmt. #ESMOAsia22 2

Reply on Twitter 1598644651665268736Retweet on Twitter 15986446516652687369Like on Twitter 159864465166526873634Twitter 1598644651665268736
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

#SABCS22 starts in only a couple of days!

Stay tuned right here 👉http://VJOncology.com👈 which will be updated soon on all the latest in #BreastCancer 👩‍⚕‍🎥🎙

@VJOncology @SABCSSanAntonio @AACR #BreastCancer #BCsm #OncoAlert

Reply on Twitter 1598694368269025282Retweet on Twitter 1598694368269025282Like on Twitter 15986943682690252822Twitter 1598694368269025282
Retweet on TwitterVJ Oncology Retweeted
matteolambeMatteo Lambertini, MD PhD@matteolambe·
December 2, 2022

Great comprehensive presentation by super @RebeccaDSing at #ESMOasia22 on #immunotherapy in early triple-negative #BreastCancer: important citation for the recent review by @ElisaAgostinett & the great algorithm for #TNBC treatment by @hoperugo

@OncoAlert @myESMO #bcsm #ImmOnc

4
Reply on Twitter 1598530488737619971Retweet on Twitter 15985304887376199716Like on Twitter 159853048873761997119Twitter 1598530488737619971
Load More

Watch all ELCC videos

View all videos
4:26
Risk model to predict delivery of adjuvant chemotherapy
Alessandro Brunelli • 24 Mar 2022
0:49
ELCC 2022: importance of the multidisciplinary team
Paul Van Schil • 14 Mar 2022
6:03
Shared decision making and human bias in thoracic oncology
Alessandro Brunelli • 24 Mar 2022
4:32
Recent advances in minimally invasive video-assisted thoracic surgery
Alan D. L. Sihoe • 16 Mar 2022

Surgery

View all videos
1:49
Tackling synchronous oligometastases
Alan D. L. Sihoe • 16 Mar 2022
1:47
The development of surgery for lung cancer with the evolution of neoadjuvant/adjuvant treatment
Paul Van Schil • 14 Mar 2022
6:03
Shared decision making and human bias in thoracic oncology
Alessandro Brunelli • 24 Mar 2022
4:32
Recent advances in minimally invasive video-assisted thoracic surgery
Alan D. L. Sihoe • 16 Mar 2022
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals